68 related articles for article (PubMed ID: 22265862)
1. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Fujimaki S; Matsuda Y; Wakai T; Sanpei A; Kubota M; Takamura M; Yamagiwa S; Yano M; Ohkoshi S; Aoyagi Y
Cancer Lett; 2012 Jun; 319(1):98-108. PubMed ID: 22265862
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
3. Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-κB activation.
Veuger SJ; Durkacz BW
DNA Repair (Amst); 2011 Feb; 10(2):235-44. PubMed ID: 21144805
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
6. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
8. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
Golding SE; Rosenberg E; Neill S; Dent P; Povirk LF; Valerie K
Cancer Res; 2007 Feb; 67(3):1046-53. PubMed ID: 17283137
[TBL] [Abstract][Full Text] [Related]
9. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy.
Crescenzi E; Palumbo G; de Boer J; Brady HJ
Clin Cancer Res; 2008 Mar; 14(6):1877-87. PubMed ID: 18347191
[TBL] [Abstract][Full Text] [Related]
10. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
11. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
13. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
[TBL] [Abstract][Full Text] [Related]
14. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
[TBL] [Abstract][Full Text] [Related]
15. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
16. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress.
Kirshner J; Jobling MF; Pajares MJ; Ravani SA; Glick AB; Lavin MJ; Koslov S; Shiloh Y; Barcellos-Hoff MH
Cancer Res; 2006 Nov; 66(22):10861-9. PubMed ID: 17090522
[TBL] [Abstract][Full Text] [Related]
19. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
[TBL] [Abstract][Full Text] [Related]
20. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
Li Y; Yang DQ
Mol Cancer Ther; 2010 Jan; 9(1):113-25. PubMed ID: 20053781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
